Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate

Estrapronicate/hydroxyprogesterone heptanoate/nandrolone undecanoate (EPC/OHPH/NU), tentative brand name Trophobolene or Trophoboline, is an injectable combination medication of estrapronicate (EPC; estradiol nicotinate propionate), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and nandrolone undecanoate (NU), an androgen/anabolic steroid, which was never marketed.^[1][2] It contained 1.3 mg EPC, 80 mg OHPH, and 50 mg NU in oil solution and was administered by intramuscular injection.^[1][2][3] The medication was developed by Théramex in the mid-to-late 1960s.^[4][1][2] It was studied for use for a variety of indications, including treatment of coronary insufficiency, growth deficiency, and osteoporosis, as well as hormonal disorders in gonadotropin deficiency.^[1]

EPC/OHPH/NU

Combination of
Estrapronicate	Estrogen
Hydroxyprogesterone heptanoate	Progestogen
Nandrolone undecanoate	Androgen; Anabolic steroid
Clinical data
Trade names	Trophobolene, Trophoboline
Other names	EPC/OHPH/NU
Pregnancy category	f
Routes of administration	Intramuscular injection
Identifiers
CAS Number	80238-09-1

In contrast to other anabolic steroid-containing preparations, EPC/OHPH/NU reportedly had no masculinizing effects, and its estrogenic component likewise reportedly had no feminizing effects.^[1] The nicotinic acid (niacin; vitamin B3) derived from estrapronicate was said to enhance the nutrient, relaxant, and antiadipose effects of the estrogenic component.^[1]

The pharmacokinetics of nandrolone undecanoate in this combination preparation have been studied as well as compared to nandrolone alone (Dynabolon).^[5]

See also

• List of combined sex-hormonal preparations § Estrogens, progestogens, and androgens